HCA Healthcare reported third quarter 2026 revenue of $19.849 billion and net income of $1.579 billion, alongside an updated full-year operating forecast in the upper half of its previously issued ranges. The company experienced an unfavorable payer mix shift due to increased uninsured volume, which negatively impacted pre-tax income by approximately $400 million.
Revenues increased 3.6 percent to $19.849 billion in the third quarter of 2026.
Net income attributable to HCA Healthcare, Inc. declined 3.9 percent to $1.579 billion.
The Board of Directors declared a quarterly cash dividend of $0.78 per share payable on December 29, 2026.
The company repurchased 7.230 million shares of its common stock at a cost of $2.970 billion during the third quarter.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From HCA Healthcare's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$75.60B
+7.1%
$28.33
+28.8%
9.0%
FY2024
$70.60B
+8.7%
$22.00
+16.0%
8.2%
FY2023
$64.97B
+7.9%
$18.97
-0.9%
8.1%
FY2022
$60.23B
+2.5%
$19.15
-9.5%
9.4%
FY2021
$58.75B
+14.0%
$21.16
+93.6%
11.8%
Frequently asked questions
When is HCA Healthcare's next earnings date?
HCA Healthcare has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did HCA Healthcare earn last quarter?
For the quarter ended Sep 2026, HCA Healthcare reported diluted EPS of $7.27 (+4.5% year over year) on revenue of $19.85B (+3.6%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.